Syra Health Overview
Valuation check: SYRA's ROE is 4.96%, above the sector sector average of -5.84%.
Get informed when a big investor buys or sells
+ Follow4.96%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for SYRA is 4.96%. That is above the sector sector average of -5.84%. Investors often review this figure alongside Syra Health's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, SYRA currently prints 4.96% for ROE, while the sector average sits near -5.84%. That is roughly 184.9% above the sector mean. Large gaps often invite a closer look at Syra Health's growth, margins, and balance sheet.
Return on Equity shows how effectively Syra Health converts resources into returns. At 4.96%, SYRA may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting SYRA's ROE (4.96%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
